Author Index to Volume 23

Abramowitz C. *See* Davous P
Abrams RC. *See* Alexopoulos GS
Adamson R. *See* Hunt DD
Ågren H. *See* Joborn C
Åkerström G. See Joborn C
Alavi A. *See* Wolf ME
Aldes LD, Prater SR, Chronister RB, Marco LA. Ketamine as a pharmacological model for tongue dyskinesia, 159
Alessi NE. *See* Dilsaver, SC
Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell Scale for depression in dementia, 271
Alfredsson G, Wiesel F-A, Tylec A. Relationships between glutamate and monoamine metabolites in cerebrospinal fluid and serum in healthy volunteers, 689
Allen, AD. Creation, evolution, and biological psychiatry, 209-le
Amori G. *See* Hughes JR
Anderson A. *See* Harbour DV
Anderson GD, Rebec GV. Clozapine and haloperidol in the amygdaloid complex: Differential effects on dopamine transmission with long-term treatment, 497
Anderson GM. *See* Todd RD
Angel C. *See* Newton JEO
Angrist B. *See* Corwin J
Angrist B. *See* Smith M
Anton RF. *See* Brown ME
Aprison MH. *See* Hingtgen JN
Arana G. *See* Hughes JR
Arnett F. *See* Smith M
Arora RC, Meltzer HY. Effect of desipramine treatment on ^{3}H-imipramine binding in the blood platelets of depressed patients, 397
Arora RC, Meltzer HY. Seasonal variation of imipramine binding in the blood platelets of normal controls and depressed patients, 217
Asnis GM. *See* Kahn RS
Atwater GE. *See* Christison GW

Backmund H. *See* Krieg J-C
Bagne CA. *See* Pomara N
Baker GB. *See* Hampson DR
Ballenger JC. *See* Brown ME
Banki CM. *See* France RD
Barocka A. *See* Rupprecht R
Barouche F. *See* Smith M
Barr G. *See* Kahn RS
Baumgartner A, Haug H-J. Thyroid hormones during sleep deprivation, 537-le
Beauclair L. *See* Csernansky JG
Beck G. *See* Rupprecht R
Beeckman N. *See* Schoups AA
Bentley P. *See* Thomas DR
Berger PA. *See* Warner MD
Bernhout E. *See* Weizman A
Biddle N. *See* Tiller JWG
Bissett G. *See* France RD
Blass JP. *See* Davidson M
Blazer DG. *See* Krishnan KRR
Blundell JE. *See* Morley JE
Bolles RC. Why you should avoid statistics, 79
Bowden CL, Huang LG, Javors MA, Johnson JM, Seleshi E, McIntyre K, Contreras S, Maas JW. Calcium function in affective disorders and healthy controls, 367
Breitling D. *See* Guenther W
Brenner RP. *See* Kahn EM
Brodie JD. *See* Smith M
Brown ME, Anton RF, Malcolm R, Ballenger JC. Alcohol detoxification and withdrawal seizures: Clinical support for a kindling hypothesis, 507
Brown SJ. *See* Friedman MJ

Carr JE. *See* Hunt DD
Carr V, Edwards J, Prior M. Urinary MHPG, platelet ^{3}H-imipramine binding and symptomatology in depression: An exploratory study of clinical heterogeneity, 560
Castrén E. *See* Kurihara M
Charlton BG. *See* Ferrier IN
Chiba T. *See* Fukushima J

Abbreviations
ed: Editorial
le: Letter to the Editor

Chouinard G. *See* Germain L
Christison GW, Atwater GE, Dunn LA, Kilts CD. Haloperidol enhancement of latent inhibition: Relation to therapeutic action? 746
Chronister RB. *See* Aldes LD
Clark C. *See* Hurwitz T
Cohen DJ. *See* Todd RD
Cohen P. Are statistics necessary? 1-ed
Cole JO. *See* Mooney JJ
Contreras S. *See* Bowden CL
Cook N. *See* Harris B
Coppola R. *See* Kahn EM
Corrigan FM, Coulter F. Neuroleptic malignant syndrome, amitriptyline, and thioridazine, 320-le
Corwin J, Herndal P, Angrist B, Rotrosen J. Neuroleptic-induced akathisia: Propranolol versus benztropine, 211-le
Coulter F. *See* Corrigan FM
Coutts RT. *See* Hampson DR
Csernansky JG, Mellentin J, Beauclair L, Lombrozo L. Mesolimbic dopaminergic supersensitivity following electrical kindling of the amygdala, 285

Danel T, Servant D, Goudemand M. Amitriptyline in the treatment of neuroleptic-induced akathisia, 186
David JJ. *See* Vieweg WVR
Davidson M, Powchik P, Davis KL. Pisa syndrome in Alzheimer's disease, 213-le
Davidson M, Zemishlany Z, Mohs RC, Horvath TB, Powchik P, Blass JP, Davis KL. 4-aminopyridine in the treatment of Alzheimer's disease, 485
Davidson M. *See* Sorokin, JE
Davies BM. *See* Tiller JWG
Davis CL. *See* Kahn J-P
Davis KL. *See* Davidson M
Davis KL. *See* Sorokin JE
Davous P. *See* Guenther W
Davous P, Roudier M, Piketty ML, Abramowitz C, Lamour Y. Pharmacological modulation of cortisol secretion and dexamethasone suppression in Alzheimer's disease, 13
Deanović Z. *See* Mück-Šeler D
de Azevedo BA, Fontana P Jr. Audiogenic seizures and the pineal gland, 734
De Potter WP. *See* Schoups AA
Deptula D. *See* Pomara N
Diepgen T. *See* Rupprecht R
DiMicco JA. *See* Hingtgen JN
Dilsaver SC. Amitriptyline and cholinergic supersensitivity, 214-le
Dilsaver SC, Majchrzak MJ, Alessi NE. Chronic treatment with amitriptyline produces supersensitivity to nicotine, 169
Dixon KN. *See* Levy AB
Duffy FH. *See* Faux SF
Dunn LA. *See* Christison GW
Dupont R. *See* Risch SC

Ebert MH. *See* Kaye WH
Edwards J. *See* Carr V
Edwardson JA. *See* Ferrier IN
Egan K. *See* Hunt DD
Ellinwood EH. *See* Krishnan KRR
Ellinwood EH Jr. A message from the president of the Society of Biological Psychiatry, 325-ed
El-Mallakh RS. Complications of concurrent lithium and electroconvulsive therapy: A review of clinical material and theoretical considerations, 595

Fairbairn AF. *See* Ferrierr IN
Faludi G, Magyar I, Tekes K, Tothfalusi L, Magyar K. Measurement of H-serotonin uptake in blood platelets in major depressive episodes, 833
Farrington J. *See* Harbour DV
Faux SF, Torello MW, McCarley RW, Shenton ME, Duffy FH. P300 in schizophrenia: Confirmation and statistical validation of temporal region deficit in P300 topography, 776
Ferrier IN, Pascual J, Charlton BG, Wright C, Leake A, Griffiths HW, Fairbairn AF, Edwardson JA. Cortisol, ACTH, and dexamethasone concentrations in a psychogeriatric population, 252
Fontana P Jr. *See* de Azevedo BA
Fowler JS. *See* Smith M
France RD. *See* Krishnan KRR
France RD, Urban B, Krishnan KRR, Bissett G, Banki CM, Nemeroff C, Speilman FJ. CSF corticotropin-releasing factor-like immunoreactivity in chronic pain patients with and without major depression, 86
Fried D, Mann JJ. Electroconvulsive treatment of a patient with known intracranial tumor, 176
Friedman D. Physostigmine, auditory P300, and Alzheimer's disease, 321-le (*with response*)
Friedman MJ, Krstulovic AM, Severinghaus JM,

Brown SJ. Altered conversion of tryptophan to kynurenine in newly abstinent alcoholics, 89
Fukushima J, Fukushima K, Chiba T, Tanaka S, Yamashita I, Kato M. Disturbances of voluntary control of saccadic eye movements in schizophrenic patients, 670
Fukushima K. *See* Fukushima J

Galloway MP. *See* Pomara N
George DT. *See* Kaye WH
Germain L, Chouinard G. Treatment of recurrent unipolar major depression with captopril, 637
Gerson B. *See* Mooney JJ
Ghadirian AM, Gianoulakis C, Nair NPV. The effect of electroconvulsive therapy on endorphins in depression, 459
Gianoulakis C. *See* Ghadirian AM
Giller AL. *See* Mason JW
Gillin JC. *See* Risch SC
Giordani B. *See* Sorokin JE
Giral P, Martin P, Soubrié P, Simon P. Reversal of helpless behavior in rats by putative 5-HT_{1A} agonists, 237
Godet J-l. *See* Guenther W
Godleski LS. *See* Vieweg WVR
Golden RN, Morris JE, Sack DA. Combined lithium-tricyclic treatment of obsessive-compulsive disorder, 181
Goli V. *See* Krishnan KRR
Golshan S. *See* Risch SC
Goudemand M. *See* Danel T
Greenhouse J. *See* Trzepacz PT
Griffiths HW. *See* Ferrier IN
Guenther W, Davous P, Godet J-L, Guillebert E, Breitling D, Rondot P. Bilateral brain dysfunction during motor activation in type II schizophrenia measured by EEG mapping, 295
Guillibert E. *See* Guenther W
Günther W. *See* Müller N
Gutkind JS. *See* Kurihara M
Gwirtsman HE. *See* Kaye WH

Hamburger SD. *See* Zametkin AJ
Hampson DR, Baker GB, Coutts RT. Neurochemical changes in rat brain amines after short- and long-term inhibition of monoamine oxidase by a low dose of tranylcypromine, 227
Haracz JL, Minor TR, Wilkins JN, Zimmermann EG. Learned helplessness: An experimental model of the DST in rats, 388
Harbour DV, Anderson A, Farrington J, Wassef A, Smith EM, Meyer WJ III. Decreased mononuclear leukocyte TSH responsiveness in patients with major depression, 797
Harris B. *See* Thomas DR
Harris B, Cook N, Warner N, Read GF, Thomas R, Riad-Fahmy D. Anxiety and the dexamethasone suppression test monitored with saliva, 698
Hashimoto M, Mukasa H, Yamada S, Nakamura J, Inanaga K. Frontal midline theta activity and platelet MAO in human subjects, 31
Haug H-J. *See* Baumgartner A
Hayaishi O. *See* Ohishi K
Herndal P. *See* Corwin J
Hetta J. *See* Joborn C
Hickok JM. *See* Todd RD
Hingtgen JN, Shekhar A, DiMicco JA, Aprison MH. Response suppression in rats after bilateral microinjection of 5-hydroxy-tryptophan in lateral hypothalamus, 711
Holcomb HH. *See* Metz JT
Hommer DW. *See* Stoner GR
Horn B. *See* Müller N
Horvath TB. *See* Davidson M
Huang LG. *See* Bowden CL
Hughes JR, Arana G, Amori G, Stewart F, Workman R. Effect of tobacco withdrawal on the Dexamethasone Suppression Test, 96
Hunt DD, Adamson R, Egan K, Carr JE. Opioids: Mediators of fear or mania, 426
Hurwitz T, Kopala L, Clark C, Jones B. Olfactory deficits in schizophrenia, 123

Inanaga K. *See* Hashimoto M

Jackson A. *See* Lyons F
Jakovljević M. *See* Mück-Šeler D
Janowsky DS. *See* Risch SC
Javors MA. *See* Bowden CL
Jecht E. *See* Rupprecht R
Jimerson DC. *See* Kaye WH
Jimerson DC. *See* Uhde TW
Joborn C, Hetta J, Rastad J, Ågren H, Åkerström G, Ljunghall S. Psychiatric symptoms and cerebrospinal fluid monoamine metabolites in primary hyperparathyroidism, 149
Joffe RT. *See* Uhde TW
Johnson JM. *See* Bowden CL
Jones B. *See* Hurwirtz T
Jones E. *See* Thomas DR
Josiassen RC, Shagass C, Roemer RA. Dealing with differential gender and age effects in

evoked potential studies of psychopathology, 612

Kahn EM, Weiner RD, Brenner RP, Coppola R. Topographic maps of brain electrical activity: Pitfalls and precautions, 628
Kahn J-P, Rubinow DR, Davis CL, Kling M, Post RM. Salivary cortisol: A practical method for evaluation of adrenal function, 335
Kahn RS, van Praag HM, Wetzler S, Asnis GM, Barr G. Serotonin and anxiety revisited, 189
Kato M. *See* Fukushima J
Kaye WH, Gwirtsman HE, George DT, Jimerson DC, Ebert MH. CSF 5-HIAA concentrations in anorexia nervosa: Reduced values in underweight subjects normalize after weight gain, 102
Kilts CD. *See* Christison GW
Kim C-E. *See* Paik, I-H
Kizuka PP. *See* Mooney JJ
Klein E, Uhde TW. 24-hour motor activity in genetically nervous and normal pointer dogs, 523
Klein I. *See* Trzepacz PT
Kleinman JE. *See* Korpi ER
Kling M. *See* Kahn J-P
Kopala L. *See* Hurwitz T
Korpi ER, Kleinman JE, Wyatt RJ. GABA concentrations in forebrain areas of suicide victims, 109
Kosten TR. *See* Mason JW
Krieg J-C, Pirke K-M, Lauer C, Backmund H. Endocrine, metabolic, and cranial computed tomographic findings in anorexia nervosa, 377
Krishnan KRR. *See* France RD
Krishnan KRR, Goli V, Ellinwood EH, France RD, Blazer DG, Nemeroff CB. Leukoencephalopathy in patients diagnosed as major depressive, 519
Krstulovic AM. *See* Friedman MJ
Kugler J. *See* Müller N
Kurihara M, Castrén E, Gutkind JS, Saito K, Saavedra JM. Characterization of β-adrenergic receptors in sections from human blood lymphocyte pellets by quantitative autoradiography, 750

Laakmann G. *See* Müller N
Laessle RG, Schweiger U, Pirke KM. Depression as a correlate of starvation in patients with eating disorders, 719
Lal KP, Saxena S, Mohan D. Tardive dystonia alternating with mania, 312
Lamour Y. *See* Davous P
Lauer C. *See* Krieg J-C
Lauwers MC. *See* Schoups AA
Leake A. *See* Ferrier IN
Lee C. *See* Paik I-H
Lerbinger, J. *See* Mooney JJ
Lesser IM. *See* Poland RE
Levey GS. *See* Trzepacz PT
Levine B. *See* Merriam AE
Levy AB, Dixon KN, Malarkey WB. Pituitary response to TRH in bulimia, 476
Levy AB, Dixon KN, Schmidt H. Sleep architecture in anorexia nervosa and bulimia, 99
Lindström LH. *See* Nyberg F
Ljunghall S. *See* Joborn C
Lombrozo L. *See* Csernansky JG
Losonczy MF. *See* Sorokin JE
Lowy MT, Meltzer HY. Stimulation of serum cortisol and prolactin secretion in humans by MK-212, a centrally active serotonin agonist, 818
Lukas SE, Mendelson JH. Electroencephalographic activity and plasma ACTH during ethanol-induced euphoria, 141
Lyons F, Martin ML, Maguire C, Jackson A, Regan CM, Shelley RK. The expression of an N-CAM serum fragment is positively correlated with severity of negative features in type II schizophrenia, 769

Maas JW. *See* Bowden CL
MacGregor RR. *See* Smith M
Maguire C. *See* Lyons F
Maguire KP. *See* Tiller JWG
Magyar I. *See* Faludi G
Magyar K. *See* Faludi G
Majchrzak MJ. *See* Dilsaver SC
Malarkey WB. *See* Levy AB
Malcolm R. *See* Brown ME
Mallott DB. *See* Schwartz BD
Mann JJ. *See* Fried D
Marco LA. *See* Aldes LD
Martin ML. *See* Lyons F
Martin P. *See* Giral P
Mason JW, Giller E, Kosten TR. Serum testosterone differences between patients with schizophrenia and those with affective disorder, 357
McCarley RW. *See* Faux SF

McCue M. *See* Trzepacz PT
McIntyre K. *See* Bowden CL
McLean S. *See* Rothman RB
Medalia A. *See* Merriam AE
Mellentin J. *See* Csernansky JG
Meltzer HY. *See* Arora RC
Meltzer HY. *See* Lowy T
Meltzer HY. *See* Metz JT
Mendelson JH. *See* Lukas SE
Merriam AE, Medalia A, Levine B. Partial complex status epilepticus associated with cocaine abuse, 515
Metz JT, Holcomb HH, Meltzer HY. Effect of 5-hydroxytryptophan on H-reflex recovery curves in normal subjects and patients with affective disorders, 602
Meyer WJ III. *See* Harbour DV
Miles A, Philbrick DRS. Melatonin and psychiatry, 405
Minor TR. *See* Haracz JL
Mohan D. *See* Lal KP
Mohs RC. *See* Davidson M
Mohs RC. *See* Sorokin JE
Mooney JJ, Schatzberg AF, Cole JO, Kizuka PP, Salomon M, Lerbinger J, Pappalardo KM, Gerson B, Schildkraut JJ. Rapid antidepressant response to alprazolam in depressed patients with high catecholamine output and heterologous desensitization of platelet adenylate cyclase, 543
Morley JE, Blundell JE. The neurobiological basis of eating disorders: Some formulations, 53
Morris JE. *See* Golden RN
Mosnaim AD. *See* Wolf ME
Mück-Šeler D, Jakovljević M, Deanović Z. Time course of schizophrenia and platelet 5-HT level, 243
Mukasa H. *See* Hashimoto M
Müller N, Günther W, Horn B, Laakmann G, Kugler J. Psychopathological changes in a patient with rhythmic midtemporal discharges after antiepileptic medication, 741

Nair NPV. *See* Ghadirian AM
Nakamura J. *See* Hashimoto M
Nemeroff C. *See* France RD
Nemeroff C. *See* Krishnan KRR
Newton JEO, Paige SR, Angel C, Reese WG. Heart rate and activity in response to natural stimuli in nervous and normal pointer dogs, 829
Nishino S. *See* Ohishi K
Noder M. *See* Rupprecht R
Nyberg F, Lindström LH, Terenius L. Reduced beta-casein levels in milk samples from patients with postpartum psychosis, 115

Ohishi K, Ueno R, Nishino S, Sakai T, Hayaishi O. Increased level of salivary prostaglandins in patients with major depression, 326
Outenreath R. *See* Risch SC

Paige SR. *See* Newton JEO
Paik I-H, Lee C, Kim C-E. Platelet MAO in schizophrenics: Relationship to symptomatology and neuroleptics, 93
Pappalardo KM. *See* Mooney JJ
Pascual J. *See* Ferrier IN
Peabody CA. *See* Warner MD
Peselow W. *See* Smith M
Philbrick DRS. *See* Miles A
Pichl J. *See* Rupprecht R
Piketty ML. *See* Davous P
Pirke K-M. *See* Krieg J-C
Pirke K-M. *See* Laessle RG
Poland RE, Rubin RT, Lesser IM. Serum dexamethasone concentrations in endogenous depressives before, during, and after treatment: Preliminary observations, 705
Pomara N, Stanley M, Rhiew HB, Bagne CA, Deptula D, Galloway MP, Tanimoto K, Verebey K, Tamminga CA. Loss of the cortisol response to naltrexone in Alzheimer's disease, 726
Porrino LJ. Different patterns of local brain energy metabolism, 214-le
Post RM. *See* Kahn J-P
Post RM. *See* Uhde TW
Powchik P. *See* Davidson M
Prater SR. *See* Aldes LD
Prior M. *See* Carr V

Quintana J. Platelet MAO deanimation of serotonin in depressed patients. Changes after imipramine treatment and clinical correlations, 44

Rapaport MH. *See* Risch SC
Rastad J. *See* Joborn C
Read GF. *See* Harris B
Rebec GV. *See* Anderson GD
Reese WG. *See* Newton JEO
Regan CM. *See* Lyons F
Rehavi M. *See* Weizman A

Renshaw PF, Wicklund S. In vivo measurement of lithium in humans by nuclear magnetic resonance spectroscopy, 465
Rhiew HB. *See* Pomara N
Riad-Fahmy D. *See* Harris B
Risch SC, Golshan S, Rapaport MH, Dupont R, Outenreath R, Gillin JC, Janowsky DS. Neuroendocrine effects of intravenous ovine corticotropin-releasing factor in affective disorder patients and normal controls, 755
Roemer RA. *See* Josiassen RC
Rondot P. *See* Guenther W
Rothman RB, McLean S. An examination of the opiate receptor subtypes labeled by [^{3}H] cycloFOXY: An opiate antagonist suitable for positron emission tomography, 435
Rotrosen J. *See* Corwin C
Rotrosen J. *See* Smith M
Roudier M. *See* Davous P
Rowe WT. *See* Vieweg WVR
Rubin RT. *See* Poland RE
Rubinow DR. *See* Kahn J-P
Rupprecht C. *See* Rupprecht R
Rupprecht M. *See* Rupprecht R
Rupprecht R, Barocka A, Beck G, Schrell U, Pichl J. Pre- and postdexamethasone plasma ACTH and β-endorphin levels in endogenous and nonendogenous depression, 531
Rupprecht R, Noder M, Jecht E, Schwartz W, Rupprecht C, Rupprecht M, Diepgen T. Pre- and postdexamethasone cortisol and prolactin levels in sexual dysfunction and normal controls, 527
Russell JAG. *See* Smith M
Ryan TA. *See* Sorokin JE

Saavedra JM. *See* Kurihara M
Sack DA. *See* Golden RN
Saito K. *See* Kurihara M
Sakai T. *See* Ohishi K
Salomon M. *See* Mooney JJ
Saxena S. *See* Lal KP
Schatzberg AF. *See* Mooney JJ
Schildkraut JJ. *See* Mooney JJ
Schmidt H. *See* Levy AB
Schoups AA, Beeckman N, Lauwers M-C, De Potter WP, Evaluation of the role of pre- and postsynaptic serotonergic receptors in electroconvulsive shock therapy, 807
Schrell U. *See* Rupprecht R
Schwartz BD, Mallott DB, Winstead DK. Preattentive deficit in temporal processing by chronic schizophrenics, 664
Schwartz BD, Winstead DK. Visible persistence in paranoid schizophrenics, 3
Schwartz W. *See* Rupprecht R
Schweiger U. *See* Laessle RG
Sedvall G. *See* Swahn C-G
Seiver LJ. *See* Sorokin JE
Seleshi E. *See* Bowden CL
Servant D. *See* Danel T
Severinghaus JM. *See* Friedman MJ
Shagass C. *See* Josiassen RC
Shamoian CA. *See* Alexopoulos GS
Shekhar A. *See* Hingtgen JN
Shelley RK. *See* Lyons F
Shenton ME. *See* Faux SF
Shiue C-Y. *See* Smith M
Simon P. *See* Giral P
Skirboll LR. *See* Stoner GR
Smith EM. *See* Harbour DV
Smith M, Wolf AP, Brodie JD, Arnett CD, Barouche F, Shiue C-Y, Fowler JS, Russell JAG, MacGregor RR, Wolkin A, Angrist B, Rotrosen J, Peselow E. Serial [^{18}F] methylspiroperidol PET studies to measure changes in antipsychotic drug D-Z receptor occupancy in schizophrenic patients, 653
Sorokin JE, Giordani B, Mohs RC, Losonczy MF, Davidson M, Siever LJ, Ryan TA, Davis KL. Memory impairment in schizophrenic patients with tardive dyskinesia, 129
Soubrié P. *See* Giral P
Speilman FJ. *See* France RD
Spradlin WW. *See* Vieweg WVR
Stanley M. *See* Pomara N
Stewart F. *See* Hughes JR
Stoner GR, Skirboll LR, Werkman S, Hommer DW. Preferential effects of caffeine on limbic and cortical dopamine systems, 761
Swahn C-G, Sedvall G. CSF creatinine in schizophrenia, 586
Szilágyi AK. Increased CSF amino acids and ventricular enlargement, 317-le

Tamminga CA. *See* Pomara N
Tanaka S. *See* Fukushima J
Tanimoto K. *See* Pomara N
Tekes K. *See* Faludi G
Terenius L. *See* Nyberg F
Thomas DR, Jones E, Warner N, Harris B,

Williams P, Bentley P. Peripheral serotonergic receptor sensitivity in senile dementia of the Alzheimer's type, 136
Thomas R. *See* Harris B
Tiller JWG, Biddle N, Maguire KP, Davies BM. The Dexamethasone Suppression Text and plasma dexamethasone in generalized anxiety disorder, 261
Todd RD, Hickok JM, Anderson GM, Cohen DJ. Antibrain antibodies in infantile autism, 644
Torello MW. *See* Faux SF
Tothfalusi L. *See* Faludi G
Trzepacz PT, McCue M, Klein I, Greenhouse J, Levey GS. Psychiatric and neuropsychological response to propranolol in Graves' disease, 678
Tyano S. *See* Weizman A
Tylec A. *See* Alfredsson G

Ueno R. *See* Ohishi K
Uhde TW. *See* Klein E
Uhde TW, Joffe RT, Jimerson DC, Post RM. Normal urinary free cortisol and plasma MHPG in panic disorder: Clinical and theoretical implications, 575
Urban B. *See* France RD

van Praag HM. *See* Kahn RS
Van Sweden B. Occipital slow EEG rhythms (3-6 Hz activity), an unreliable marker, 318-le
Verebey K. *See* Pomara N
Vieweg WVR, Weiss NM, David JJ, Rowe WT, Godleski LS, Spradlin WW. Treatment of psychosis, intermittent hyponatremia, and polydipsia (PIP syndrome) using lithium and phenytoin, 25

Waddington JL. *See* Youssef HA
Warner MD, Peabody CA, Berger PA. Olfactory deficits and Down's syndrome, 837
Warner N. *See* Harris B
Warner N. *See* Thomas DR
Wassef A. *See* Harbour DV
Waziri R. Glycine therapy of schizophrenia, 210-le
Weiner RD. *See* Kahn EM
Weiss NM. *See* Vieweg WVR
Weitz R. *See* Weizman A
Weizman A, Bernhout E, Weitz R, Tyano S, Rehavi M. Imipramine binding to platelets of children with attention deficit disorder with hyperactivity, 491
Werkman S. *See* Stoner GR
Wetzler S. *See* Kahn RS
Wicklund S. *See* Renshaw PF
Wiesel F-A. *See* Alfredsson G
Wilkins JN. *See* Haracz JL
Williams P. *See* Thomas DR
Winstead DK. *See* Schwartz BD
Wolf AP. *See* Smith M
Wolf ME, Alavi A, Mosnaim AD. Posttraumatic stress disorder in Vietnam veterans. Clinical and EEG findings: Possible therapeutic effects of carbamazepine, 642
Wolkin A. *See* Smith M
Workman R. *See* Hughes JR
Wortis J
  Conflicts of interest, 215-ed
  The history of psychiatry, 107-ed
  Privitization, 433-ed
  Quality of life, 541-ed
  Report from the editorial office, 759-ed
Wright C. *See* Ferrier IN
Wyatt RJ. *See* Korpi ER

Yamada S. *See* Hashimoto M
Yamashita I. *See* Fukushima J
Young RC. *See* Alexopoulos GS
Youssef HA, Waddington JL. Primitive (developmental) reflexes and diffuse cerebral dysfunction in schizophrenia and bipolar affective disorder: Overrepresentation in patients with tardive dyskinesia, 791

Zádor G. Tardive dysmentia in Hungary, 429-le
Zametkin AJ, Hamburger SD. The effect of methylphenidate on urinary catecholamine excretion in hyperactivity: A partial replication, 350
Zemishlany Z. *See* Davidson M
Zimmerman EG. *See* Haracz JL

Subject Index to Volume 23

ACTH. *See* Adrenocorticotrophic hormone (ACTH)
Adenylate cyclase
  antidepressants and, 543
Adrenal function
  salivary cortisol and, 335
  β-adrenergic receptors, 750
  quantitative autoradiography of, 750
Adrenocorticotrophic hormone (ACTH) DST and, 531
  in elderly, 252
  in ethanol-induced euphoria, 141
Affective disorders. *See also specific disorder*
  calcium function in, 367
  corticotropin-releasing factor in, 755
  melatonin and, 405
  serotonin effects on H-reflex in, 602
  testosterone in, 357
Age
  evoked potential studies and, 612
Akathisia
  amitriptyline in, 186
  propranolol vs. benztropine in, 211-le
Alcohol drinking
  ACTH and, 141
Alcoholism
  tryptophan conversion and, 89
  withdrawal seizures in, 507
Alprazolam
  adenylate cyclase and, 543
Alzheimer's disease
  4-aminopyridine in, 485
  cortisol-naltrexone response in, 726
  DST in, 13
  physostigmine and P300 in, 321-le
  Pisa syndrome in, 213-le
  serotonin and, 136
4-aminopyridine
  in Alzheimer's disease, 485
Amitriptyline
  cholinergic supersensitivity and, 214-le
  in neuroleptic-induced akathisia, 186
  neuroleptic malignant syndrome and, 320-le
  nicotine supersensitivity and, 320-le
Amygdala kindling, 285
Animal models
  of anxiety, 523, 829
  of depression, 711
  of tongue dyskinesia, 159
Anorexia nervosa
  corticotropin-releasing factor and, 53
  CT in, 377
  serotonin in, 102
  sleep in, 99
Antidepressants. *See also specific agents*
  adenylate cyclase and, 543
  melatonin and, 405
  serotonin agonists as, 237
  tricyclic with lithium in obsessive-compulsive disorder, 181
Anxiety
  animal model of, 523, 829
  DST and, 261, 698
  serotonin and, 189
Audiogenic seizures, 734
Auditory evoked potentials
  P300 and physostigmine in Alzheimer's disease, 321-le
  P300 in schizophrenia, 776
Autism, infantile
  antibrain antibodies in, 644
Autoradiography
  of β-adrenergic receptors, 750

Benzodiazepines
  serotonin and, 189
Benztropine
  propranolol vs. in akathisia, 211-le
Beta-casein
  in postpartum psychosis, 115
Biological Psychiatry editorial policy, 759-ed
Bipolar disorder
  primitive reflexes in, 791
Brain mapping, 628

Abbreviations
ed: Editorial
le: Letter to the Editor

Brain tumor
ECT with, 176
Bulimia
neuropeptide Y in, 53
sleep in, 99
TRH response in, 476
Buspirone
in learned helplessness, 237

Caffeine
dopamine and, 761
Calcium
in affective disorders, 367
psychiatric symptoms and, 149
Captopril
in depression, 637
Carbamazepine
in posttraumatic stress disorder, 642
Catecholamines
antidepressant response and, 543
methylphenidate effects on, 350
Cerebrospinal fluid (CSF)
creatinine in, 586
glutamate-monoamine relationships in, 689
research with, 317-le
Cholecystokinin
eating disorders and, 53
Chronic pain syndrome
depression and, 86
Clonidine
and DST in Alzheimer's disease, 13
Clozapine
dopamine transmission and, 497
Cocaine abuse
status epilepticus in, 515
Computed tomography (CT)
in anorexia nervosa, 377
Conflicts of interest, 215-ed
Cornell Scale for Depression in Dementia, 271
CORRESPONDENCE
Amitriptyline and cholinergic supersensitivity, 214
Creation, evolution, and biological psychiatry, 209
Different patterns of local brain energy metabolism, 214
Glycine therapy of schizophrenia, 210
Increased CSF amino acids and ventricular enlargement, 317
Neuroleptic-induced akathisia: Propranolol versus benztropine, 211
Neuroleptic malignant syndrome, amitriptyline, and thioridazine, 320
Occipital slow EEG rhythms (3-6 Hz activity), an unreliable marker, 318
Physostigmine, auditory P300, and Alzheimer's disease (with response), 321
Pisa syndrome in Alzheimer's disease, 213
Tardive dysmentia in Hungary, 429
Thyroid hormones during sleep deprivation, 537
Corticotropin-releasing factor
in affective disorders, 755
in anorexia nervosa, 53
in chronic pain and/or depression, 86
Cortisol
in elderly, 252
MK-212 and, 818
-naltrexone response in Alzheimer's disease, 726
in panic disorder, 575
salivary, 335
sexual dysfunction and, 527
Creatinine
in schizophrenia, 586
CSF. *See* Cerebrospinal fluid (CSF)
CT. *See* Computed tomography (CT)
CycloFOXY
in PET, 435

Dementia
Cornell scale for depression in, 271
Depression
alprazolam response in, 543
animal model of, 711
calcium function in, 367
captopril in, 637
chronic pain and, 86
-dementia scale, 271
desipramine imipramine-binding effects in, 397
ECT effect on endorphins in, 459
leukoencephalopathy in, 519
MAO-serotonin activity in, 44
MHPG and imipramine binding in, 560
mononuclear leukocyte TSH production in, 797
platelet serotonin uptake in, 833
prostaglandins in, 326
seasonal variation of imipramine binding in, 217
starvation and, 719
treatment and DST response in, 705
Desipramine
imipramine binding effects of, 397
Dexamethasone Suppression Test (DST)
ACTH and, 531

in Alzheimer's disease, 13
anxiety and, 698
in anxiety disorder, 261
in elderly, 252
endorphins and, 531
learned helplessness model and, 388
in sexual dysfunction, 527
tobacco withdrawal and, 96
treatment of depression and, 705
Dogs
genetically nervous, 523, 829
Dopamine
caffeine effects on, 761
eating disorders and, 53
kindled seizures and, 285
neuroleptic effects on, 497
Down's syndrome
olfaction in, 837
DST. *See* Dexamethasone Suppression Test (DST)

Eating disorders
neurobiology of, 53
sleep in, 99
starvation and depression in, 719
TRH response in, 476
ECT. *See* Electroconvulsive therapy (ECT)
EDITORIALS
Are statistics necessary? 1
Conflicts of interest, 215
The history of psychiatry, 107
A message from the president of the Society for Biological Psychiatry, 325
Privitization, 433
Quality of life, 541
Report from the editorial office, 759
The whereabouts of the why, 651
EEG. *See* Electroencephalography (EEG)
Elderly
Cornell scale for, 271
DST in, 252
Electroconvulsive therapy (ECT)
endorphins and, 459
lithium with, 595
in patient with brain tumor, 176
serotonergic receptors in, 807
Electroencephalography (EEG)
of brain dysfunction in schizophrenia, 295
brain mapping by, 628
of posttraumatic stress disorder, 642
rhythmic midtemporal discharges in, 741
slow occipital rhythms in, 318-le
Endorphins
DST and, 531
ECT effect on, 459
Euphoria
ethanol-induced, 141
Evoked potentials
age and gender effects on, 612
auditory in Alzheimer's disease, 321-le
auditory in schizophrenia, 776
Experimentation
conflicts of interest in, 215-ed
corporate support of, 433-ed
with CSF, 317-le
statistics in, 1-ed, 79
Extroversion-introversion
theta rhythm and MAO in, 31

Fear
motor activity and, 523
opioids and, 426
Frontal midline theta activity
MAO and, 31

GABA
anxiety and, 189
suicide and, 109
Gender
evoked potential studies and, 612
Glutamate-monoamine relationships, 689
Glycine
in schizophrenia, 210-le
Graves' disease
propranolol in, 678

Haloperidol
dopamine transmission and, 497
latent inhibition and, 746
Heart rate
in genetically nervous dogs, 829
Helplessness, learned
as DST model, 388
serotonin and, 237
Hoffman reflex
serotonin and, 602
5-hydroxyindolacetic acid (5-HIAA)
in anorexia nervosa, 102
5-hydroxytryptophan
hypothalamic injection of, 711
Hyperactivity
imipramine binding in, 491
methylphenidate effect on catecholamines in, 350
Hyperparathyroidism

psychiatric symptoms in, 149
Hyponatremia, psychosis, and polydipsia. *See* PIP syndrome

Imipramine
MAO-serotonin activity and, 44
Imipramine binding
depressive symptomatology and, 560
desipramine and, 397
in hyperactivity, 491
seasonal variation in, 217
Immune response
in infantile autism, 644
stress and, 209-le
Impotence
DST in, 527
Infantile autism
antibrain antibodies in, 644
Information processing
visual in schizophrenia, 3, 664

Ketamine
in tongue dyskinesia model, 159

Latent inhibition
haloperidol and, 746
Leukoencephalopathy
in depression, 519
Ligand binding, 435
Lithium
ECT with, 595
NMR measurement of, 465
in PIP syndrome, 25
with tricyclics in obsessive-compulsive disorder, 181

Mania
opioids and, 426
tardive dystonia with, 312
MAO. *See* Monoamine oxidase
Melatonin, 405
Memory
in schizophrenia with tardive dyskinesia, 129
Methylphenidate
catecholamine effects in hyperactivity, 350
MHPG
depressive symptomatology and, 560
in panic disorder, 575
MK-212, 818
Monoamine metabolites
-glutamate relationships, 689
in hyperparathyroidism, 149
Monoamine oxidase (MAO)
in schizophrenia, 93
-serotonin activity in depression, 44
short- and long-term inhibition of, 227
theta rhythm and, 31
Mononuclear leukocyte
-TSH responsiveness in depression, 797
Motor activity
in genetically nervous dogs, 523

Naltrexone
-cortisol response in Alzheimer's disease, 726
National Institutes of Health, 433-ed
N-CAM. See Neural cell adhesion molecule (N-CAM)
Neural cell adhesion molecule (N-CAM)
in schizophrenia, 769
Neuroleptic(s)
amitriptyline in akathisia induced by, 186
benztropine vs. propranolol in akathisia induced by, 211-le
dopamine transmission and, 497
MAO and, 93
olfaction and, 123
PET studies of, 653
Pisa syndrome and, 213-le
Neuroleptic malignant syndrome
amitriptyline and thioridazine withdrawal and, 320-le
Neuropeptide Y
in bulimia, 53
Neurotransmitters
eating disorders and, 53
suicide and, 109
Nicotine
amitriptyline and, 169
NMR. *See* Nuclear magnetic resonance (NMR)
Norepinephrine
eating disorders and, 53
Nuclear magnetic resonance (NMR)
lithium measurement by, 465

Obsessive-compulsive disorder
lithium-tricyclic treatment of, 181
serotonin and, 189
Occipital slow EEG rhythms, 318-le
Olfaction
in Down's syndrome, 837
in schizophrenia, 123
Opioids
eating disorders and, 53
ECT effect on, 459

in fear and mania, 426
in postpartum psychosis, 115
receptor subtypes, 435

Pain
depression and, 86
Panic disorder
cortisol and MHPG in, 575
serotonin and, 189
Paranoid schizophrenia
visible persistence in, 3
PET. *See* Positron emission tomography (PET)
Phenytoin
in PIP syndrome, 25
Physostigmine
auditory P300 and, 321-le
DST and, 13
Pineal gland
audiogenic seizures and, 734
PIP syndrome
lithium and phenytoin in, 25
Pisa syndrome, 213-le
Polydipsia, psychosis, and hyponatremia. *See* PIP syndrome
Positron emission tomography (PET)
cycloFOXY in, 435
drug receptor occupancy studies by, 653
Postpartum psychosis
beta-casein levels in, 115
Posttraumatic stress disorder, 642
Preattentive processing
in schizophrenia, 664
Prolactin
MK-212 and, 818
Propranolol
benztropine vs. in akathisia, 211-le
in Graves' disease, 678
Prostaglandins
in depression, 326
Psychiatry
history of, 107-ed
melatonin in, 405
Psychosis
in hyperparathyroidism, 149
hyponatremia and polydipsia with. *See* PIP syndrome
postpartum, 115
Publication, 759-ed

Quality of life, 541-ed
Quantitative autoradiography
of β-adrenergic receptors, 750

Rat
5-hydroxytryptophan injection in, 711
learned helplessness in, 388
kindled seizures in, 285
serotonin and helplessness behavior in, 237
short- and long-term MAO inhibition in, 227
tongue dyskinesia in, 159
Reflexes
primitive in tardive dyskinesia, 791
serotonin effects on, 602
Research
conflicts of interest in, 215-ed
with CSF, 317-le
privitization of, 433-ed
publication of, 759-ed
statistics in, 1-ed, 79
Rhythmic midtemporal discharges, 741

Saccadic eye movements
in schizophrenia, 670
Salivary measurements
of anxiety with DST, 698
cortisol, 335
prostaglandin, 326
Schizophrenia
bilateral brain dysfunction in, 295
CSF creatinine in, 586
glycine in, 210-le
kindled seizures and, 285
MAO in, 93
melatonin in, 405
memory and tardive dyskinesia in, 129
N-CAM serum fragment in, 769
olfactory deficits in, 123
P300 in, 776
PET drug receptor studies in, 653
preattentive processing deficit in, 664
primitive reflexes in, 791
saccadic eye movement control in, 670
serotonin in, 243
testosterone in, 357
visible persistence in, 3
Seasonal variation
in imipramine binding, 217
Seizures
alcohol withdrawal, 507
amygdala-kindled, 285
cocaine abuse and, 515
pineal gland and, 734
Serotonin
alcoholism and, 89
Alzheimer's disease and, 136

anxiety and, 189
eating disorders and, 53, 102
-H-reflex effects, 602
learned helplessness and, 237
-MAO activity in depression, 44
MK-212 agonist to, 818
platelet uptake of in depression, 833
receptors for in ECT, 807
schizophrenia and, 243
Sexual dysfunction
DST in, 527
Sleep
in eating disorders, 99
Sleep deprivation
thyroid hormones during, 537-le
Smoking
DST and withdrawal from, 96
Starvation, 719
Statistics
overuse of, 1-ed, 79
Status epilepticus
in cocaine abuse, 515
Stress
immune response and, 209-le
Suicide
GABA and, 109

Tardive dyskinesia
amitriptyline vs. akathisia in, 186
animal model of, 159
mania with, 312
memory and, 129
primitive reflexes in, 791
Tardive dysmentia, 429-le
Tardive dystonia. *See* Tardive dyskinesia
Testosterone
in affective disorders vs. schizophrenia, 357
Theta rhythm
platelet MAO and, 31
Thioridazine
neuroleptic malignant syndrome and, 320
Thyroid hormones
during sleep deprivation, 537-le
Thyrotropin (TSH)
mononuclear leukocyte production of in depression, 797
Thyrotropin-releasing hormone (TRH)
response to in bulimia, 476
Tongue dyskinesia
animal model of, 159
Topographic brain maps, 628
Tranylcypromine
short- and long-term effects of, 227
TRH. *See* Thyrotropin-releasing hormone
Tryptophan
-kynurenine conversion in newly abstinent alcoholics, 89
TSH. *See* Thyrotropin (TSH)

Ventricular enlargement
in anorexia nervosa, 377
CSF studies and, 317-le
Visible persistence
in paranoid schizophrenia, 3